Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imagion BiosystemsASX:IBX +8.33% Cash Ratio is 0.44 as of Dec. 2025, which is 83% below its 10-year median of 2.65. The stock has 4 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, Imagion Biosystems ranks worse than 69.71% on this metric.
Imagion Biosystems has a Cash Ratio of 0.44. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Imagion Biosystems's Cash Ratio or its related term are showing as below:
ASX:IBX'
s Cash Ratio Range Over the Past 10 Years
Min: 0.04 Med: 2.65 Max: 20.2
Current: 0.44
During the past 9 years, Imagion Biosystems's highest Cash Ratio was 20.20. The lowest was 0.04. And the median was 2.65.
ASX:IBX's Cash Ratio is ranked worse than 69.71% of 208
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.965
vs ASX:IBX: 0.44
Imagion Biosystems (ASX:IBX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Imagion Biosystems Cash Ratio Related Terms
Imagion Biosystems Cash Ratio Historical Data
* Premium members only.
The historical data trend for Imagion Biosystems's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Imagion Biosystems's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imagion Biosystems Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Imagion Biosystems's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imagion Biosystems (ASX:IBX) has a Cash Ratio of 0.44 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Imagion Biosystems and its competitors. This is 83% below median its historical median of 2.65. Over the past decade, Imagion Biosystems' Cash Ratio has ranged from 0.04 to 20.20. According to the industry distribution chart, Imagion Biosystems ranks #145 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 69.7%.
Is Imagion Biosystems' Cash Ratio too high?
Imagion Biosystems' current Cash Ratio of 0.44 is 83% below median its 10-year median of 2.65. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 20.20. The Medical Diagnostics & Research industry median Cash Ratio is 0.97. Imagion Biosystems' value of 0.44 is 54.4% below this industry median. Based on the distribution chart, Imagion Biosystems ranks #145 out of 208 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Imagion Biosystems' Cash Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Imagion Biosystems ranks #145 out of 208 companies for Cash Ratio. This places Imagion Biosystems in the lower half of its industry. The industry median Cash Ratio is 0.97. Imagion Biosystems' value of 0.44 is 54.4% below this benchmark. Historically, Imagion Biosystems' own Cash Ratio has ranged from 0.04 to 20.20 over the past decade. While the company's 10-year median is 2.65 vs. the industry median of 0.97, Imagion Biosystems has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 0.97, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imagion Biosystems's current Cash Ratio of 0.44 is 54.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Imagion Biosystems and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imagion Biosystems's current Cash Ratio is 0.44, which is 83% below median its own 10-year median of 2.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (ASX:IBX) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.13, compared to a current price of A$0.01 — trading 98.8% below its estimated fair value. The current Cash Ratio is 0.44, which is 83% below median its 10-year median of 2.65 and 54.4% below the Medical Diagnostics & Research industry median of 0.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Imagion Biosystems (ASX:IBX), the current Cash Ratio is 0.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IBX has been successfully added to your 
